Foot drop in patients treated with bortezomib – a case series and review of the literature

References

• Basset M, Milani P, Nuvolone M, et al. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Adv. 2020;4(17):4175–4179.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dialoupi I, Gavriatopoulou M, et al. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv. 2019;3(20):3002–3009.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116(19):3743–3750.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593–1599.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. IJMS. 2021;22(2):888.
   Google Scholar
• Geisler S. Vincristine- and bortezomib-induced neuropathies – from bedside to bench and back. Exp Neurol. 2021;336:113519.
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110(5):1042–1049.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Singh M, Thomas VM, Mulay S. Bortezomib-induced motor neuropathy: a case report. J Oncol Pharm Pract. 2020;26(6):1549–1552.
   PubMed Web of Science ®Google Scholar
• Mauermann ML, Blumenreich MS, Dispenzieri A, et al. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle Nerve. 2012;46(6):970–977.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Jacobus S, Vesole DH, et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010;24(8):1406–1411.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27(21):3518–3525.
   PubMed Web of Science ®Google Scholar
• Tenstad HB, Mose K, Voss A. Herpes zoster infection-induced common peroneal nerve paresis resulting in foot drop in a patient with eosinophilic fasciitis: a case report. Scand J Rheumatol. 2020;49(3):251–252.
   PubMed Web of Science ®Google Scholar
• Majeed A, Ullah W, Hamadani AA, et al. First reported case of peroneal tenosynovitis caused by coccidioides immitis successfully treated with fluconazole. BMJ Case Rep. 2016;2016:bcr2016216804.
   PubMedGoogle Scholar
• Argyriou AA, Makridou A, Karanasios P, et al. Axonal common peroneal nerve palsy and delayed proximal motor radial conduction block following infliximab treatment. J Pain Symptom Manage. 2009;38(5):e3–e5.
   PubMedGoogle Scholar
• Subramaniam K, Hughes A, Pavli P. Foot drop developing during infliximab therapy for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):E24–E25.
   PubMed Web of Science ®Google Scholar
• Boula AM, Mantadakis E, Xilouri IM, et al. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Am J Hematol. 2005;79(3):216–219.
   PubMed Web of Science ®Google Scholar
• Kelly JJ Jr, Kyle RA, Miles JM, et al. The spectrum of peripheral neuropathy in myeloma. Neurology. 1981;31(1):24–31.
   PubMed Web of Science ®Google Scholar
• Mele G, Coppi MR, Melpignano A, et al. Paralytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two cases. Clin Exp Med. 2016;16(1):99–101.
   PubMed Web of Science ®Google Scholar
• Stratogianni A, Tosch M, Schlemmer H, et al. Bortezomib-induced severe autonomic neuropathy. Clin Auton Res. 2012;22(4):199–202.
   PubMed Web of Science ®Google Scholar
• Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008;119(11):2507–2512.
   PubMed Web of Science ®Google Scholar
• Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086–1095.
   PubMed Web of Science ®Google Scholar
• Sanada Y, Nakazato T, Suzuki K, et al. Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma. Jpn J Clin Hematol. 2010;51(4):264–269. [Rinsho ketsueki]
   PubMedGoogle Scholar
• Inayat A, Marwat QU, Hayat W, et al. Brucellosis presenting with pancytopenia and foot drop. Cureus. 2020;12(9):e10293.
   PubMed Web of Science ®Google Scholar